Key Highlights

  • Decoy Therapeutics reported a 148% expansion in Q2 net losses to $2.37 million.
  • The wider loss was primarily attributed to intensified R&D investments following the IMP3ACT program Merger and legacy expenditure.
  • Quarterly Revenue of $227,629 was generated entirely via a Gates Foundation grant.
  • The company holds an $8.3 million cash reserve, bolstered by a recent June private placement.

Decoy Therapeutics reported a 148% expansion in Q2 net losses to $2.37 million, primarily attributed to intensified R&D investments following the IMP3ACT program merger and legacy expenditure.

What Happened

Quarterly revenue of $227,629 was generated entirely via a Gates Foundation grant, with an $8.3 million cash reserve bolstered by a recent June private placement.

Market Reaction

The disclosed information does not include stock price or trading data for Decoy Therapeutics following the Q2 results.

Outlook

Continued reliance on Gates Foundation grant funding, alongside the company's $8.3 million cash reserve following its June private placement, is likely to remain relevant for Decoy Therapeutics' financial trajectory going forward.